Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedMay 21, 2026
DataAggregated Company Financials
Companies322
  • 7D-0.1%
  • 3M-3.9%
  • 1Y38.7%
  • YTD1.2%

Last week, the Pharma industry hasn't moved much but Bristol-Myers Squibb is up 3.8% in that time. As for the the longer term, the industry is up 39% over the past 12 months. Looking forward, earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 21 May 2026US$2.3tUS$425.2bUS$66.3b14.8x34.7x5.4x
Sat, 18 Apr 2026US$2.2tUS$408.1bUS$66.8b16.8x33.3x5.5x
Mon, 16 Mar 2026US$2.3tUS$406.1bUS$72.0b17.4x31.8x5.6x
Wed, 11 Feb 2026US$2.4tUS$411.7bUS$74.2b21.3x32x5.8x
Fri, 09 Jan 2026US$2.3tUS$402.6bUS$71.5b19.7x32.4x5.8x
Sun, 07 Dec 2025US$2.2tUS$402.8bUS$71.4b19.5x30.2x5.3x
Tue, 04 Nov 2025US$1.9tUS$396.4bUS$71.6b17.9x26.8x4.8x
Thu, 02 Oct 2025US$1.8tUS$387.9bUS$60.9b19.4x30x4.7x
Sat, 30 Aug 2025US$1.8tUS$387.9bUS$61.0b20x28.9x4.5x
Mon, 28 Jul 2025US$1.8tUS$384.0bUS$62.2b18.2x29.2x4.7x
Wed, 25 Jun 2025US$1.7tUS$382.7bUS$61.2b17.9x28.2x4.5x
Fri, 23 May 2025US$1.7tUS$382.6bUS$61.2b17.3x27x4.3x
Sun, 20 Apr 2025US$1.7tUS$380.5bUS$48.4b16.1x36.1x4.6x
Tue, 18 Mar 2025US$1.8tUS$380.5bUS$35.2b16.2x52.6x4.9x
Thu, 13 Feb 2025US$1.9tUS$380.8bUS$38.9b18x47.9x4.9x
Sat, 11 Jan 2025US$1.8tUS$369.3bUS$31.2b16.7x57.5x4.9x
Mon, 09 Dec 2024US$1.9tUS$373.8bUS$30.6b19.3x61.3x5x
Wed, 06 Nov 2024US$1.9tUS$373.5bUS$29.7b19.8x63.3x5x
Fri, 04 Oct 2024US$2.0tUS$364.1bUS$25.2b18.5x79x5.5x
Sun, 01 Sep 2024US$2.1tUS$364.1bUS$25.5b18.1x81.5x5.7x
Tue, 30 Jul 2024US$1.9tUS$357.5bUS$12.8b16.2x152.1x5.4x
Thu, 27 Jun 2024US$2.0tUS$357.6bUS$14.0b15.7x140.8x5.5x
Sat, 25 May 2024US$1.9tUS$358.3bUS$14.1b17.9x134.5x5.3x
Mon, 22 Apr 2024US$1.8tUS$357.7bUS$29.8b20.6x59.9x5x
Wed, 20 Mar 2024US$1.9tUS$355.3bUS$22.5b19.8x83.9x5.3x
Fri, 16 Feb 2024US$1.9tUS$354.9bUS$22.9b33.3x81.3x5.2x
Sun, 14 Jan 2024US$1.8tUS$375.2bUS$33.9b26.3x52.6x4.7x
Tue, 12 Dec 2023US$1.7tUS$375.1bUS$33.9b26.7x48.9x4.4x
Thu, 09 Nov 2023US$1.7tUS$375.0bUS$34.2b21.6x48.5x4.4x
Sat, 07 Oct 2023US$1.7tUS$381.8bUS$43.8b18.5x38.2x4.4x
Mon, 04 Sep 2023US$1.7tUS$381.4bUS$43.7b19.6x39.7x4.5x
Wed, 02 Aug 2023US$1.7tUS$379.1bUS$44.0b19.2x38.5x4.5x
Fri, 30 Jun 2023US$1.7tUS$392.8bUS$60.1b19.1x29x4.4x
Sun, 28 May 2023US$1.7tUS$392.9bUS$60.6b17.8x27.6x4.3x
Price to Earnings Ratio

27.6x


Total Market Cap: US$1.7tTotal Earnings: US$60.6bTotal Revenue: US$392.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.9x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 34.7x which is lower than its 3-year average PE of 53.9x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 3.1% per year over the last three years.
  • Revenues for these companies have grown 2.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.32%
Healthcare-0.29%
Pharma-0.13%
Pharma-0.13%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BMY Bristol-Myers SquibbUS$58.543.8%
+US$4.4b		24.6%PE16.4x
LLY Eli LillyUS$1.02k0.3%
+US$2.8b		40.5%PE35.9x
ZTS ZoetisUS$79.717.2%
+US$2.3b		-50.6%PE12.5x
JAZZ Jazz PharmaceuticalsUS$239.012.9%
+US$419.1m		120.8%PE509.2x
LQDA LiquidiaUS$61.777.3%
+US$371.7m		270.8%PE246.3x

Latest News

LLY
US$1,018.87
Eli Lilly
7D
0.3%
1Y
40.5%
MRK
US$113.00
Merck
7D
-0.4%
1Y
46.8%
SEPN
US$28.01
Septerna
7D
13.2%
1Y
209.2%
Analysis Article • 3h

New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN)

Septerna, Inc. ( NASDAQ:SEPN ) shareholders will have a reason to smile today, with the analysts making substantial...
GHRS
US$22.54
GH Research
7D
3.0%
1Y
91.2%
TEVA
US$34.32
Teva Pharmaceutical Industries
7D
-5.3%
1Y
107.4%
ELAN
US$20.85
Elanco Animal Health
7D
-4.4%
1Y
65.2%
JNJ
US$229.32
Johnson & Johnson
7D
-0.5%
1Y
49.7%
BLTE
US$143.36
Belite Bio
7D
-6.6%
1Y
113.0%
ALMS
US$22.04
Alumis
7D
-11.3%
1Y
361.1%
PFE
US$25.79
Pfizer
7D
-0.7%
1Y
11.9%
VTRS
US$16.59
Viatris
7D
-4.5%
1Y
95.6%
Narrative Update • May 18

VTRS: FY26 Guidance And March Investor Event Will Shape Re Rating Potential

Analysts have raised their Viatris price target by $1.78 to $17.50, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research updates on Viatris point to a more constructive stance on the stock, with some firms lifting their valuation targets as they revisit earnings, cost savings and long term guidance assumptions.
ZTS
US$79.71
Zoetis
7D
7.2%
1Y
-50.6%
JAZZ
US$239.01
Jazz Pharmaceuticals
7D
2.9%
1Y
120.8%
BMY
US$58.54
Bristol-Myers Squibb
7D
3.8%
1Y
24.6%
Narrative Update • May 18

BMY: Pipeline Execution And Macro Shifts Will Shape Future Risk Balance

Analysts now see Bristol-Myers Squibb’s fair value edging down by $0.08 to $62.96, as they factor in slightly weaker revenue growth and profit margin assumptions alongside a higher future P/E, even as recent Street price target moves reflect mixed views on the stock’s pipeline and macro setup. Analyst Commentary Recent Street commentary on Bristol-Myers Squibb highlights a wide range of views on execution risk, pipeline delivery and how those factors may feed into valuation over the next few years.
LQDA
US$61.77
Liquidia
7D
7.3%
1Y
270.8%
Analysis Article • May 13

Upgrade: Analysts Just Made A Captivating Increase To Their Liquidia Corporation (NASDAQ:LQDA) Forecasts

Shareholders in Liquidia Corporation ( NASDAQ:LQDA ) may be thrilled to learn that the analysts have just delivered a...
CORT
US$59.06
Corcept Therapeutics
7D
3.5%
1Y
-22.1%
Narrative Update • May 11

CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside

Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.